0000914475 2026-07-31 2026-07-31 0000914475 1 2026-07-31 2026-07-31 shares iso4217:USD pure 0000914475 NEUROCRINE BIOSCIENCES, INC. S-8 S-8 EX-FILING FEES N/A Equity false Common stock, $0.001 par value per share, 2025 Equity Incentive Plan true 4000000 175.365 701460000 0.0001381 96871.63 701460000 96871.63 0 96871.63 <div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of common stock of Neurocrine Biosciences, Inc. (the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">“Registrant”</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) that become issuable under the Registrant’s 2025 Equity Incentive Plan (the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">“2025 Plan”</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s common stock, as applicable.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2) Estimated in accordance with Rule 457(c) and (h) solely for the purpose of calculating the registration fee on the basis of 175.365 per share of common stock, which represents the average of the high and low prices of the Registrant's common stock as reported on The Nasdaq Global Select Market on July 24, 2026.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3) Represents 4,000,000 additional shares of Registrant’s common stock that were added to the shares authorized for issuance under the 2025 Plan on May 27, 2026 pursuant to approval of the stockholders at the 2026 Annual Meeting of Stockholders.</span></div>